Preview

Медицинский Совет

Расширенный поиск

КАРДИОВАСКУЛЯРНАЯ БЕЗОПАСНОСТЬ ГЛИПТИНОВ АКЦЕНТ НА АЛОГЛИПТИН

https://doi.org/10.21518/2079-701X-2017-3-32-37

Полный текст:

Аннотация

Сахарный диабет 2-го типа представляет собой хроническое прогрессирующее заболевание с возрастающей распространенностью. Не прекращается разработка новых стратегий лечения диабета, среди которых стоит отметить и препараты, влияющие на «инкретиновый эффект». Ингибиторы дипептидилпептидазы 4-го типа (иДПП-4, глиптины) представляют собой группу пероральных сахароснижающих препаратов инкретинового ряда, вызывающих усиление глюкозозависимой активности β-клеток и подавление избыточной секреции глюкагона α-клетками поджелудочной железы. Эта группа сахаро снижающих препаратов получила широкое распространение благодаря ряду таких важных преимуществ, как нейтральное влияние на массу тела, низкий риск гипогликемии, удобный режим приема и хорошая приверженность к лечению. Показанная в ходе многоцентровых международных исследований эффективность и безопасность лечения дает возможность широкого применения глиптинов в клинической практике.

Об авторах

Н. А. Петунина
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России
Россия
д.м.н., профессор,


Е. В. Гончарова
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России
Россия


С. А. Потапова
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России
Россия


Список литературы

1. IDF Diabetes Atlas – Seventh Edition, 2015. Online version of IDF Diabetes Atlas. Доступно по: www.diabetesatlas.org.

2. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Сахарный диабет, 2015, 18(1S): 1-112.

3. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia, 2002, 45(7): 937-948.

4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med, 2009, 360: 129-139.

5. FDA. Guidance for industry: diabetes mellitusevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Доступно по: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.

6. Elrick H, Stimmler L, Hlad CJ, Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab, 1964, 24(10): 1076–1082.

7. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med, 1992, 326(20): 1316–1322.

8. Потапова С.А., Гончарова Е.В., Петунина Н.А. Сравнительная характеристика кардиоваскулярной безопасности сахароснижающих препаратов. Лечебное дело, 2016, 2: 76-88.

9. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des Devel Ther, 2013, 7: 989-1001. doi: 10.2147/DDDT.S37647.

10. Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when coadministered in patients with type 2 diabetes. Curr Med Res Opin, 2006, 22: 1939-1947.

11. He YL, Sabo R, Picard F, Wang Y, Herron J, Ligueros-Saylan M, Dole WP. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin, 2009, 25: 1265-1272.

12. Mistry GC, Bergman AJ, Zheng W, Hreniuk D, Zinny MA, Gottesdiener KM, Wagner JA, Herman GA, Ruddy M. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol, 2008, 66: 36–42.

13. Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol, 2007, 47: 159–164.

14. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol, 2009, 49: 1210-1219.

15. Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, Forst T. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus–results from an exploratory study. Cardiovasc Diabetol, 2013, 12: 59.

16. Graefe-Mody U, Huettner S, Stähle H., Ring A., Dugi K.A. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther, 2010, 48: 367-374.

17. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012, 33: 187-215.

18. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res, 2012, 9: 109-116.

19. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab, 2013, 15: 668-673.

20. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin, 2011, 27(Suppl 3): 57-64.

21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007, 356: 2457-2471.

22. Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med, 2012, 157: 601-610.

23. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015, 373: 232-242.

24. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol, 2013, 12: 3.

25. Nathewani A, Lebault A, Byiers S, Gimpelewicz C, Chang IH. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. Program and abstracts of the Ame rican Diabetes Association 66th Scientific Sessions, Washington, DC. June 9-13, 2006. 474 p.

26. Diess D, Bosi E, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1diabetes using real-time continuous glucose monitoring. Diabetes Care, 2006, 29: 2730-2732.

27. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Vildaglip tin therapy reduces postprandial intestinal triglyceride rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49(9): 2049-2057.

28. Ligueros-Saylan M, Schweizer A, Dickinson S, Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. EASD Poster presentation. 2009.

29. He Y-L, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin, 2007, 23: 1131-1138.

30. Ayalasomayajula SP, Dole K, He YL, LiguerosSaylan M, Wang Y, Campestrini J, Humbert H, Sunkara G. Evaluation of the potential for steadystate pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. CurrMed Res Opin, 2007, 23(12): 2913-2920.

31. McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao Q, Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab, 2015, 17(11): 1085-1092.

32. Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, Choi SH, Jang HC, Lim S. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract, 2015, 109: 141-148.

33. Forst T, Koch C, Dworak M. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr Med Res Opin, 2015, 31: 1079-1084.

34. Ishii M, Shibata R, Kondo K, Kambara T, Shimizu Y, Tanigawa T, Bando YK, Nishimura M, Ouchi N, Murohara T. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitricoxide synthase-dependent mechanism. J Biol Chem, 2014, 289: 27235–27245.

35. Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, Sugiyama H, Akazawa K, Yonezawa T, Wada J, Ito H. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic betaadrenergic stimulation in rats. Cardiovasc Diabetol, 2014, 13: 43.

36. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013, 369: 1317-1326.

37. Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care, 2015, 38: 1145-1153.

38. Eurich DT, Weir DL, Simpson SH, Senthilselvan A, McAlister FA. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med, 2015, 33(5): 621-630.

39. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 2014, 130: 1579-1588.

40. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: metaanalysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther, 2014, 32(4): 147-158.

41. Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 2015, 14: 57.

42. Rosenstock J, Marx N, Kahn SE, Zinman B, Kas telein JJ, Lachin JM, Bluhmki E, Patel S, Johan sen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res, 2013, 10: 289-301.

43. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes: CAROLINA®. Diab Vasc Dis Res, 2015, 12: 164-174.

44. FDA doctor. Clinical Trial CARMELINA Study with Linagliptin in Patients with Type II Diabetes. 2015. http://fdadoctor.com/clinicaltrial-carmelina-study-with-linagliptin-inpatients-with-type-ii-diabetes/.

45. Groop P-H, Cooper ME, Perkovic V, Emser A, Woerle H-J, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care, 2013, 36: 3460-3468.

46. Von Eynatten M, Gong Y, Emser A, Woerle H-J. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol, 2013, 12: 60.

47. McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care, 2013, 36: 237-244.

48. Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D, Kusaka H, Ma M, Nakagawa T, Lin B, Kim-Mitsuyama S. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol, 2014, 13: 157.

49. Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol, 2014, 13: 154.

50. Covington P, Christopher R, Davenport M, Fleck P, Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhi bitor alogliptin: a randomized, double-mind, placebocontrolled, multiple-dose study in adult pati ents with type 2 diabetes. Clin Ther, 2008, 30: 499-512.

51. Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm, 2014, 71: 103-109.

52. Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother, 2013, 47: 1532-1539.

53. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract, 2009, 63(1): 46-55.

54. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl pepti-dase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin, 2009, 25(10): 2361–2371.

55. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab, 2009, 11(2): 167-176.

56. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial with an openlabel, long-term extension. Curr Med Res Opin, 2011, 27(Suppl 3): 21-29.

57. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab, 2009, 11(12): 1145-1152.

58. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. Examination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J, 2011, 162: 620-626.

59. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother, 2009, 10: 503-512.

60. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 2015, 385: 2067-2076.

61. Kaku K, Katou M, Igeta M, Ohira T, Sano H. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab, 2015, 17(12): 1198-1201.

62. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, on behalf of the Alogliptin Study 010 Group. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebocontrolled study. Diabetes Care, 2008, 31(12): 2315-2317. doi:10.2337/dc08-1035.

63. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab, 2014, 16: 1239-1246. doi: 10.1111/dom.12377.

64. Терехова А.Л., Петунина Н.А. Кардиоваскулярная безопасность в терапии сахарного диабета 2-го типа: Фокус на алоглиптин. Медицинский Совет, 2016, 3: 38-46.


Просмотров: 73


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)